Introducing Jorge A. Bezerra, M.D., Our 2020 AASLD President
William F. Balistreri – 11 July 2020
Gut Microbes Take It to the Next Level? First Insights Into Farnesoid X Receptor Agonists of Microbial Origin
Martin Lenicek, Steven W.M. Olde Damink, Frank G. Schaap – 10 July 2020
Correction
9 July 2020
Living Donor Liver Transplantation for Imatinib‐Resistant Gastrointestinal Stromal Tumor Liver Metastases: A New Therapeutic Option in Transplant Oncology
Maria Abbondanza Pantaleo, Massimo Del Gaudio, Matteo Ravaioli, Matteo Cescon, Margherita Nannini – 8 July 2020
Self‐Organizing Human Induced Pluripotent Stem Cell Hepatocyte 3D Organoids Inform the Biology of the Pleiotropic TRIB1 Gene
Deepti Abbey, Susannah Elwyn, Nicholas J. Hand, Kiran Musunuru, Daniel J. Rader – 8 July 2020 – Establishment of a physiologically relevant human hepatocyte‐like cell system for in vitro translational research has been hampered by the limited availability of cell models that accurately reflect human biology and the pathophysiology of human disease. Here we report a robust, reproducible, and scalable protocol for the generation of hepatic organoids from human induced pluripotent stem cells (hiPSCs) using short exposure to nonengineered matrices.
Telomeres, p53, Hepatocyte Nuclear Factor 4α, and Liver Disease
Mark Antkowiak, Richard M. Green – 7 July 2020
Telomeres, p53, Hepatocyte Nuclear Factor 4α, and Liver Disease
Mark Antkowiak, Richard M. Green – 7 July 2020
Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus
Isabelle Chemin, Flor H. Pujol, Caroline Scholtès, Carmen L. Loureiro, Fouzia Amirache, Massimo Levrero, Fabien Zoulim, Jimena Pérez‐Vargas, François‐Loïc Cosset – 6 July 2020
Acute Confusion Following Liver Transplantation: HE or Not HE, That Is the Question
Nwe Ni Than, Jose Guillain Cataluna, Avik Majumdar – 6 July 2020
Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
Surain B. Roberts, Marwa Ismail, Gowthami Kanagalingam, Andrew L. Mason, Mark G. Swain, Catherine Vincent, Eric M. Yoshida, Cynthia Tsien, Jennifer A. Flemming, Harry L.A. Janssen, Gideon M. Hirschfield, Bettina E. Hansen, Aliya F. Gulamhusein, the Canadian Network for Autoimmune Liver Disease – 6 July 2020 – Patients with primary biliary cholangitis (PBC) with incomplete response to ursodeoxycholic acid are at risk of disease progression and need additional therapy.